A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention | Zendy

Dominic Mitchell | Zendy; Jason R. Guertin | Zendy; Anick Dubois | Zendy; MariePierre Dubé | Zendy; JeanClaude Tardif | Zendy; Ange Christelle Iliza | Zendy; Fiorella Fanton-Aita | Zendy; Alexis Matteau | Zendy; Jacques LeLorier | Zendy

Open Access

A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention

Author(s) -

Dominic Mitchell,

Jason R. Guertin,

Anick Dubois,

MariePierre Dubé,

JeanClaude Tardif,

Ange Christelle Iliza,

Fiorella Fanton-Aita,

Alexis Matteau,

Jacques LeLorier

Publication year - 2018

Publication title -

molecular diagnosis and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.322

H-Index - 42

eISSN - 1179-2000

pISSN - 1177-1062

DOI - 10.1007/s40291-018-0323-2

Subject(s) - statin , medicine , rhabdomyolysis , myopathy , pharmacogenomics , dyslipidemia , physical therapy , intensive care medicine , pharmacology , disease

Statin (HMG-CoA reductase inhibitor) therapy is the mainstay dyslipidemia treatment and reduces the risk of a cardiovascular (CV) event (CVE) by up to 35%. However, adherence to statin therapy is poor. One reason patients discontinue statin therapy is musculoskeletal pain and the associated risk of rhabdomyolysis. Research is ongoing to develop a pharmacogenomics (PGx) test for statin-induced myopathy as an alternative to the current diagnosis method, which relies on creatine kinase levels. The potential economic value of a PGx test for statin-induced myopathy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research